Wang Z, Zhang HM, Guo YR, Li LL. Molecular mechanisms of Biyu decoction as treatment for psoriasis: A network pharmacology and molecular docking study. World J Clin Cases 2022; 10(21): 7224-7241 [PMID: 36158000 DOI: 10.12998/wjcc.v10.i21.7224]
Corresponding Author of This Article
Ling-Ling Li, PhD, Doctor, Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 5 Haiyuncang Road, Dongcheng District, Beijing 100700, China. linglingli1980@163.com
Research Domain of This Article
Dermatology
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang Z, Zhang HM, Guo YR, Li LL. Molecular mechanisms of Biyu decoction as treatment for psoriasis: A network pharmacology and molecular docking study. World J Clin Cases 2022; 10(21): 7224-7241 [PMID: 36158000 DOI: 10.12998/wjcc.v10.i21.7224]
World J Clin Cases. Jul 26, 2022; 10(21): 7224-7241 Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7224
Molecular mechanisms of Biyu decoction as treatment for psoriasis: A network pharmacology and molecular docking study
Zi Wang, Hao-Min Zhang, Yuan-Rui Guo, Ling-Ling Li
Zi Wang, Hao-Min Zhang, Yuan-Rui Guo, Ling-Ling Li, Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
Author contributions: Li LL designed the research; Wang Z, Zhang HM, and Guo YR performed the research; Zhang HM, and Guo YR analyzed the data; Wang Z wrote the paper.
Supported bythe National Natural Science Foundation of China (NSFC), No. 81874393.
Institutional review board statement: Because the data from public databases are publicly available and open-access, this study do not require approval by the local ethics committees. This study followed public databases access policies and publication guidelines.
Clinical trial registration statement: This registration policy applies to prospective, randomized, controlled trials only.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors declare that there is no conflict of interest regarding the publication of this paper.
Data sharing statement: Technical appendix, statistical code, and dataset available from the manuscript.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Corresponding author: Ling-Ling Li, PhD, Doctor, Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 5 Haiyuncang Road, Dongcheng District, Beijing 100700, China. linglingli1980@163.com
Received: January 17, 2022 Peer-review started: January 17, 2022 First decision: March 16, 2022 Revised: March 24, 2022 Accepted: June 4, 2022 Article in press: June 4, 2022 Published online: July 26, 2022 Processing time: 174 Days and 19.3 Hours
ARTICLE HIGHLIGHTS
Research background
Psoriasis (PSO) is a major public health challenge, causing great physical, psychological and economic burden. Biyu Decoction (BYT) has clear clinical efficiency in treating PSO.
Research motivation
The molecular mechanism of BYT treatment for PSO is still unclear.
Research objectives
To identify the targets and pathways through which BYT interferes with PSO.
Research methods
Therapeutic targets for BYT were predicted by network pharmacology and validated by molecular docking.
Research results
A total of 213 gene targets corresponding to 117 active components of BYT can intervene in PSO through a variety of biological pathways highly related to PSO, such as Th17 cell differentiation and TNF signaling Pathway. The stability of these biological reactions was verified by molecular docking.
Research conclusions
BYT can the pathogenesis of PSO with multiple targets.
Research perspectives
The results of this study could serve as a fundamental basis for the further exploration in the in vitro and in vivo experiments for clinical promotions.
